Retinal Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mirrored similar events around the country, including outside the nations capitol. All in response to Police Shootings in recent days caught on camera in louisianna and minnesota. As Dallas Police continue to investigate tonight, the police chief said the devisive necessary must stop. We dont feel much support most days lets not make today most days. Learning more about the shoot here carried out the deadly attack in dallas, a friend of Micah Xavier Johnson told the Associated Press he didnt see this coming. Said johnson was well educated and wasnt really political. Said he saw johnson about a...

Rockville, Md.—The Association for Research in Vision and Ophthalmology (ARVO) Foundation congratulates David Zacks, MD, PhD — 2023 recipient of the Kreissi

Published: Feb 12, 2021 By Kate Goodwin After announcing topline data from two identical Phase III trials, Roche’s Genentech has doubled down on data and is now Faricimab is an injectable treatment to maintain the vision of patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). These are two of the leading causes of blindness with nAMD responsible for 90% of all blindness resulting from AMD.   Genetech’s Lucentis was the  first FDA-approved drug proven to restore sight in nAMD patients. Since 2006 it had been a game-chang...

Posted on 7938 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from four Phase III studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema (DME) and neovascular or “wet” age-related macular degeneration (nAMD). The studies consistently showed that faricimab, given at intervals of up to four months, offered non-inferior vision gains compared to aflibercept, given every two months. Approximately half of people eligible for exte...